Ritter pharmaceuticals inc (RTTR)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-1,667

-444

-2,167

-2,815

-4,705

-6,625

-4,646

-3,584

-2,012

-2,216

-2,010

-1,963

-1,673

-7,590

-3,526

-4,139

-3,128

-2,222

-3,080

-2,097

-1,387

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1

1

1

1

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

27

26

26

26

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

1

1

1

1

1

1

1

1

1

0

0

0

0

Stock-based compensation

56

74

94

122

146

84

171

178

212

149

203

248

294

-

-

-

-

-

-

-

-

Stock based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

317

334

329

377

462

751

881

799

Settlement of accounts payable

535

-

-

-

-

1,787

0

0

-893

-

0

0

0

-

-

-

-

-

-

-

-

Amortization of discount on available-for-sale debt securities

-

0

0

16

-26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale securities

-

-

0

-0

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accrued interest receivable

-0

-0

-1

-13

-37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-332

-261

328

0

20

-44

-72

361

9

-

-85

196

-7

-

180

-78

-45

-119

266

-14

-0

Other assets

-

-

-

-

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

517

-561

137

295

-2,378

2,381

769

720

-703

-507

653

457

-261

-974

1,067

-325

1,388

-97

-552

386

-80

Accrued expenses

132

38

-151

-1,521

406

999

-125

389

-309

257

-478

-225

-321

314

-24

727

-409

318

-676

540

50

Lease liabilities

-29

-28

-27

-27

-13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

0

0

0

-13

-1

-0

-0

-0

-0

0

0

0

0

1

11

0

1

-1

-0

-0

Net cash used in operating activities

-1,163

-1,664

-2,423

-3,883

-6,544

-3,202

-3,757

-2,657

-3,714

-2,221

-1,545

-1,677

-1,953

-

-

-

-

-

-

-

-

Cash flows provided by investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,316

-1,725

-1,418

-3,408

-275

-618

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

6

10

0

0

Sale of investments in marketable debt securities

-

0

0

2,749

4,249

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows provided by investing activities

-

0

0

2,747

4,249

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities
Proceeds from the issuance of shares from ATM Agreement

4,509

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-7

-6

-10

0

0

Stock issuance costs of ATM Agreement

-156

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of warrants

614

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of shares for Aspire equity line

450

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercising of options on common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

7

6

0

2

0

4

0

0

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-153

Net cash provided by financing activities

5,416

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

4,252

-257

-2,423

-1,136

-2,295

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2

1,000

4

17,959

-153

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-3,714

19,073

-1,856

322

-1,953

-1,405

-2,319

-3,316

-1,731

-425

-3,414

17,683

-771

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

179

-

0

0

0

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow activities:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

0

0

0

0

Cash paid for taxes

14

0

0

1

185

-

-

-

0

0

0

0

0

8

9

63

0

0

0

0

0

Supplemental disclosure of non-cash financing activities:
Conversion of preferred stock to common stock

1,288

2,289

804

0

3,453

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for lease liabilities

-

0

0

0

198

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities arising from obtaining right-of-use assets

-

-84

0

0

184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares for settlement of accounts payable

109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

178

149

Accretion of discount on Series C preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

31

31